Shanghai Ethypharm

Shanghai Ethypharm is the Chinese affiliate of the French specialty pharmaceutical company Ethypharm, focusing on the development, manufacturing, and commercialization of essential medicines. The company specializes in therapeutic areas including Central Nervous System (CNS) disorders, hospital care, and internal medicine, with a particular emphasis on pain management and addiction treatment. Shanghai Ethypharm is recognized for its expertise in innovative drug delivery systems (DDS), such as modified-release and orodispersible formulations. It operates a state-of-the-art manufacturing facility in the Qingpu District of Shanghai, which supplies the local market with key products like Etiasa (mesalazine) for inflammatory bowel disease. The company continues to expand its portfolio through strategic acquisitions, such as the recent addition of mesalazine suppositories to its gastrointestinal offerings.